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High microbiota reactivity of adult human intestinal
IgA requires somatic mutations
Johanna Kabbert1, Julia Benckert2,5, Tim Rollenske3, Thomas C.A. Hitch4, Thomas Clavel4, Vuk Cerovic1, Hedda Wardemann3, and Oliver Pabst1
The gut is home to the body’s largest population of plasma cells. In healthy individuals, IgA is the dominating isotype, whereas
patients with inflammatory bowel disease also produce high concentrations of IgG. In the gut lumen, secretory IgA binds
pathogens and toxins but also the microbiota. However, the antigen specificity of IgA and IgG for the microbiota and
underlying mechanisms of antibody binding to bacteria are largely unknown. Here we show that microbiota binding is a
defining property of human intestinal antibodies in both healthy and inflamed gut. Some bacterial taxa were commonly
targeted by different monoclonal antibodies, whereas others selectively bound single antibodies. Interestingly, individual
human monoclonal antibodies from both healthy and inflamed intestines bound phylogenetically unrelated bacterial species.
This microbiota cross-species reactivity did not correlate with antibody polyreactivity but was crucially dependent on the
accumulation of somatic mutations. Therefore, our data suggest that a system of affinity-matured, microbiota cross-
species–reactive IgA is a common aspect of SIgA–microbiota interactions in the gut.
Introduction
IgA-secreting plasma cells constitute a major leukocyte popula-
tion in the human gut. IgM-secreting plasma cells are also pre-
sent (Magri et al., 2017) and, in patients with inflammatory
bowel disease (IBD), high concentrations of IgG are detectable in
the intestinal lumen (Macpherson et al., 1996). However, the
specificity of intestinal antibodies for luminal antigen, including
components of the gut microbiota, are largely unknown (Pabst
and Slack, 2020).
Polymeric IgA and IgM are actively transported across the
epithelial cell layer into the gut lumen by the polymeric Ig re-
ceptor. During this process, a fragment of the polymeric Ig re-
ceptor becomes covalently bound to the antibody to generate a
hybrid molecule referred to as secretory Ig (SIg; Brandtzaeg,
2009; Stadtmueller et al., 2016). In the human gut lumen, dif-
ferent antibody isotypes show differential binding to members
of the microbiota, resulting in selective coating by SIgA, SIgM,
and IgG (Fadlallah et al., 2019; Magri et al., 2017; Palm et al.,
2014). Ig coating of a given bacterial species can result in dif-
ferent outcomes ranging from extinction/loss of the Ig-coated
bacteria (typically observed only for pathogens), to no detectable
effects on colonization levels, or even an increase in colonization
(Donaldson et al., 2018; Moor et al., 2017; Peterson et al., 2015).
The fraction of SIgA-coated members of the gut microbiota
varies along the intestinal tract, ranging from ∼60% of total
bacteria in the proximal small intestine to∼10% in feces (Bunker
et al., 2015; van derWaaij et al., 1996). Notably, many taxa coated
by SIgA in the colon are also coated in the small intestine, sug-
gesting that microbiota-reactive IgA is primarily induced in the
proximal gut segments (Bunker et al., 2015).
Recently, the functional properties of intestinal bacteria
coated by endogenous polyclonal IgA have been reported. Sort
purification of SIgA-coated bacteria followed by 16S ribosomal
RNA (rRNA) gene amplicon sequencing revealed enrichment of
distinct bacterial taxa in IgA-coated fractions (Bunker et al.,
2015; Kau et al., 2015; Palm et al., 2014). Mice colonized with
SIgA-coated gut bacteria showed increased susceptibility to co-
litis (Palm et al., 2014) and enhanced diet-dependent enteropa-
thy (Kau et al., 2015) compared with animals colonized with
noncoated bacteria. These observations show that SIgA coating
is linked to distinct functional properties of gut bacteria.
However, we are largely ignorant when it comes to de-
scribing defined antigens bound by IgA or the precise mecha-
nisms of how IgA binds to members of the microbiota. SIgA can
bind to microorganisms by canonical Fab-dependent binding as
well as noncanonical interactions between antibody and mi-
crobiota (Pabst and Slack, 2020). Noncanonical interactions are
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unaffected by somatic mutations in the Fab region of the anti-
body and rely on glycan moieties associated with the Fc part
of the antibody and the secretory component (Mathias and
Corthesy, 2011; Pabst and Slack, 2020). The relevance of such
noncanonical binding to members of the microbiota is not well
defined.
To investigate the specificity of IgA for the microbiota, a
recent study in mice showed that single mAbs bound to diverse
but defined subsets of microbial populations (Bunker et al.,
2017). This binding profile was associated with antibody poly-
reactivity and was independent of somatic mutations (Bunker
et al., 2017). Yet, in the human gut, germline (GL)-encoded IgA is
virtually absent, and IgA-secreting plasma cells are character-
ized by high numbers of somatic mutations (Barone et al., 2011;
Benckert et al., 2011; Lindner et al., 2015). Indeed, human mAbs
directed against LPS O-antigens of Klebsiella pneumoniae recog-
nize intestinal microbes, and this binding required somatic
mutations (Rollenske et al., 2018). We suggest referring to this
phenomenon of single mAbs binding to different bacterial spe-
cies as cross-species reactivity (Pabst and Slack, 2020). Mech-
anistically, cross-species reactivity is not fully understood.
Here, we characterized a panel of IgG and IgA mAbs derived
from human small intestine of both healthy donors (HDs) and
Crohn’s disease (CD) patients. This approach allowed us to
contrast the microbiota-binding capacity of IgA and IgG, but also
to compare antibody specificity for members of the gut micro-
biota under healthy and inflamed conditions. Our data demon-
strate that microbiota binding is a frequent property of IgA and
IgG under both healthy and inflamed conditions. In most cases,
the binding capacity and spectrum of human IgA was crucially
dependent on somatic mutations and did not correlate with
polyreactivity. We therefore suggest that, in adult humans, a
system of affinity matured, microbiota cross-species–reactive
IgA is a common aspect of SIgA–microbiota interactions in
the gut.
Results
Microbiota-reactive IgA and IgG antibodies are abundant in the
adult human small intestine
To investigate the microbiota reactivity and specificity of Fab-
dependent canonical binding of human intestinal antibodies
under steady-state and inflammatory conditions, we generated
two collections of recombinant mAbs. A first set of 162 anti-
bodies was derived from the terminal ileum of three HDs, re-
ported previously (Benckert et al., 2011). A second collection of
118 antibodies was obtained and generated from patients with
IBD (CD; Table S1). For both HD and CD donors, IgA- and IgG-
derived antibodies were cloned from single lamina propria
IgA+CD38+CD27+ and IgG+CD38+CD27+ plasmablasts/plasma
cells, respectively. To allow for unbiased comparison of gut
microbiota binding of IgA- and IgG-derived antibodies, all mAbs
were expressed as human IgG1 in mammalian cells (Benckert
et al., 2011; Tiller et al., 2008). Thus, differences between indi-
vidual antibodies with respect tomicrobiota-binding capacity and
specificity reflect differences in canonical Fab-dependent antigen
binding, whereas potential noncanonical binding properties of
endogenous SIgA are not captured in this approach. In total, we
generated and screened 280 human mAbs for their microbiota
reactivity (IgA, 105 from HD and 84 from CD donors; IgG, 57
from HD and 34 from CD donors).
To avoid potential competition for epitope binding between
these recombinant antibodies and endogenous IgA, fecal samples
from Rag2-deficient mice, which lack B cells and therefore sol-
uble Ig, were used. Microbial cells were identified by flow cy-
tometry based on their scatter profiles and staining intensity
with the DNA-binding dye Syto9. Material isolated from feces of
germ-free mice and in vitro–cultured Escherichia coliwas used to
establish precise gating of bacteria (Fig. 1 A).
Bacterial staining with the control antibody (mG053;
Wardemann et al., 2003) and antibody-free cell culture super-
natant showed variable background staining (0.52 ± 0.31, mean
± SD, n = 36). Thus, to exclude the possibility of false positives,
we considered binding of ≥1% total microbial cells as the
threshold of antibody reactivity. This definition of antibody-
positive populations does not exclude the possibility of true
binding of antibodies with lower binding capacity to bacteria.
Both IgA and IgG mAbs showed a wide spectrum of micro-
biota reactivity, including antibodies with nomicrobiota binding
and antibodies binding >5% of all fecal bacteria (Fig. 1, B and C).
We therefore categorized antibodies to have no/low (0–1% of
bacteria), intermediate (1–5%), and high (>5%) binding capacity
for gut bacteria. Antibodies with high binding capacity for gut
bacteria were present among mAbs of both IgA and IgG origin
(Fig. 1 B). Notably, high microbiota-binding capacity was ob-
served in both collections of mAbs but clearly more pronounced
in antibodies derived from CD patients compared with HD-
derived antibodies (Fig. 1 C). We therefore conclude that
microbiota-binding capacity is a characterizing property of a
substantial proportion of human intestinal IgA and IgG anti-
bodies in both healthy and inflamed gut.
Intestinal IgA antibodies bind diverse but distinct groups of
gut bacteria
To further characterize the binding specificity and mechanisms
regulating the binding of human intestinal antibodies to mi-
crobiota, we selected 15 high-microbiota-reactive mAbs cloned
from IgA plasmablasts/plasma cells (six fromHDs, nine from CD
patients; Fig. 1 C) for further analyses (Fig. S1 A). Two of the
selected HD IgAmAbs are clonally related (HD3a14 and HD3a75),
suggesting that the two antibodies might show similar proper-
ties and specificity.
All selected antibodies showed high microbiota-binding ca-
pacity across independent experiments performed with murine
donor feces obtained from different cages and collected at dif-
ferent times (Fig. S1 B). Notably, across the experiments, we
observed marked variability in the percentage of antibody-
bound bacteria. Performing experiments on aliquots of pooled
fecal material reduced variability (Fig. S1 B), suggesting that
microbial variations in the fecal material contributed to the
observed variability in antibody binding.
Major variability with respect to microbiota-binding profiles
was also apparent when testing high-microbiota-reactive mAbs
for binding to bacteria present in human feces. Screening of
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human fecal samples required direct fluorochrome conjugation
of selected mAbs because of the high background binding of the
anti-human IgG1 secondary antibody to human fecal bacteria
(likely reflecting endogenous IgG coating of human gut bacte-
ria). To cover a range of different microbiota configurations,
mAbs were tested against five samples obtained from HDs and
five samples from IBD patients. Indeed, 16S rRNA sequencing
revealed notable differences in microbiota β-diversity between
healthy and IBD samples (not depicted). Seven of eight anti-
bodies selected for high microbiota reactivity based on the
screening of Rag2-deficient mouse feces also showed high re-
activity to bacteria isolated from several human fecal samples
(Fig. 2, A and B). However, the binding profile of mAbs differed
greatly between individual samples (Fig. 2 B). Such distinct
binding profiles likely reflect differences in microbial species
composition but may also be influenced by additional factors
modulating antibody binding capacity, such as transcriptomic
state of gut microbiota and environmental modification of
antibody epitopes. Irrespectively, these data show that high
microbiota reactivity is a feature shared across a broad range of
fecal samples. Considering the marked variability between dif-
ferent human donors with respect to the percentage of mAb
binding to bacteria as well as the uncertainty with respect to the
underlying factors affecting mAb binding and the impact of
endogenous Ig coating the microbiota, we chose to further
characterize mAb binding to mouse microbiota. Aiming at a
robust description of antibody-bound taxa (Fig. S1 B), two sep-
arate sets of experiments were performed using feces from non-
cohoused mice. To investigate which microbial taxa were targeted
by the selected mAbs, bacteria bound and unbound by high-
microbiota-reactive mAbs were sort-purified by FACS and sub-
jected to 16S rRNA gene amplicon sequencing (Fig. 3 A).
We first examined α-diversity parameters (richness and
Shannon effective counts) to assess the complexity of input and
sorted bacterial populations (Fig. 3 B). No major differences
were observed for richness, implying that each individual mAb
Figure 1. Microbiota-reactive IgA antibodies are abundant in the adult human small intestine. (A) IgA-free microbes were isolated from feces of SPF
Rag2-deficient mice. Gates were set according to in vitro–cultured GFP-expressing E. coli and fecal material isolated from germ-free mice (top row). GFP signal
or Syto9 nucleic acid dye were used to identify bacteria (bottom row). Anti-human IgG1 antibody was used to detect mAb-positive fecal bacteria. Repre-
sentative staining is depicted for previously described low (mGO53) and high (ED38) polyreactive control antibodies (Meffre et al., 2004; Wardemann et al.,
2003) and staining with supernatant from nontransfected HEK-cells (Med CTRL) on feces from SPF Rag2-deficient mice. (B and C) Two collections of an-
tibodies derived from IgA- or IgG-expressing plasmablasts/plasma cells from HDs (Benckert et al., 2011) or CD patients were screened for reactivity to microbes
isolated from SPF Rag2-deficient mice. (B) Symbols represent individual antibodies (162 HDmAbs and 118 CDmAbs) assayed in one representative experiment.
Binding to <1% of bacteria was considered background (dashed line). Groups were compared by Kruskal–Wallis and post hoc Mann–Whitney U test (**, P <
0.001; ***, P < 0.0001). (C) Antibodies were categorized according to the following binding capacities: no/low (0–1% of bacteria), intermediate (1–5%), and
high (≥5%). FSC-A, forward scatter area; SSC-A, side scatter area; SSC-H, side scatter height.
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bound multiple bacterial taxa. Antibody-positive samples showed
a notable spread in Shannon effective counts (which integrates
the evenness of molecular species and can be considered as a
proxy for numbers of dominant species), suggesting a po-
tential heterogeneity of antibody binding profiles. Notably,
α-diversity of antibody-positive samples did not correlate
with bacteria binding capacity (Fig. 3 C), i.e., samples sorted
with antibodies binding to a comparably smaller percentage of
all gut bacteria showed a similarly high diversity as samples
purified with antibodies binding to a very large proportion of
all gut bacteria. This further underlines that antibodies with
high binding capacities to gut microbiota show distinct binding
specificities.
To assess and visualize differences between samples
(β-diversity), we used principal coordinates analysis (PCoA) based
on generalized UniFrac distances (Chen et al., 2012). Comparison
of antibody-positive samples of HD- and CD donor–derived
antibodies, i.e., healthy and inflamed intestine, revealed largely
overlapping binding profiles to gut bacterial populations (Fig. 3 D,
left panel). This indicates that, although CD is often accompanied
by major shifts in the microbiota composition (Fadlallah et al.,
2018), gut inflammation is not necessarily associated with an
extensive shift in IgA specificity for particular members of the
microbiota. In contrast, β-diversity analysis revealed major differ-
ences between antibody-positive and antibody-negative
bacterial fractions across both sets of experiments (Fig. 3 D,
middle and right panel). In conclusion, both α- and β-diversity
analyses indicate that single monoclonal intestinal antibodies
do not enrich for individual bacterial species but instead spe-
cifically bind broadly to distinct groups of gut bacteria.
Intestinal IgA shows cross-species reactivity
To identify bacterial taxa that explain the observed difference in
β-diversity, we examined the relative abundance of individual
Figure 2. Binding capacity of intestinal IgA antibodies to human gut bacteria shows donor-dependent variability. Bacteria were isolated from fecal
samples of five healthy individuals (HF) and five ulcerative colitis (UC) patients and stained with directly conjugated mAbs. (A) Representative FACS plots of
microbiota reactivity of mAbs to human gut bacteria. Microbes were stained with Syto9 nucleic acid dye, and microbiota reactivity of AF647 directly conjugated
mAbs was assessed by flow cytometry. Data are representative of two independent experiments (mean ± SD). (B) Fecal samples were characterized by 16S
rRNA amplicon sequence analysis. Dendrogram clustering of individual fecal samples is based on their bacterial genomic sequence composition. Heat map
depicts binding capacity of single mAbs to bacteria isolated from respective HF and UC donors (organized as a dendrograms) displayed as mean of two in-
dependent experiments.
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operational taxonomic units (OTUs) in antibody-positive and
-negative samples. For all mAbs investigated, antibody-positive
samples contained multiple, phylogenetically distant, OTUs (Fig.
S2). However, OTUs highly abundant in the antibody-positive
samples were typically still detectable in the antibody-negative
samples (Fig. S2). Therefore, we expressed the capacity of in-
dividual antibodies to enrich for distinct OTUs as an enrichment
index. The index considers the ratio of relative OTU abundances
in the antibody-positive and -negative samples plus the OTU
abundance in the positive sample (see Materials and methods).
Indeed, for all antibodies tested, the enrichment index high-
lighted several OTUs (Fig. 4). 16 OTUs were targeted by multiple
antibodies, as defined by a twofold enrichment in the antibody-
positive fraction for at least three individual mAbs tested, in-
dicating that these OTUs are preferential targets of intestinal
antibodies (Fig. 4 and Fig. S2). We will refer to these OTUs as
commonly targeted OTUs.
Taxonomic assignment of these commonly targeted OTUs
included microbial members of the main abundant phyla in the
mouse gut, Firmicutes, Proteobacteria, Bacteroidetes, and De-
ferribacteres (Fig. 4 and Fig. S2) such as Enterocloster bolteae
(OTU 16), Mucispirillum schaedleri (OTU 40), Alcaligenes faecalis
(OTU 41), Helicobacter typhlonius (OTU 6), and several species that
were identity matched to members of the family Muribaculaceae
Figure 3. Intestinal IgA antibodies bind diverse groups of gut bacteria. (A) Representative illustration of antibody-positive (mAb pos bac) and antibody-
negative bacteria (mAb neg bac) obtained by cell sorting. The diversity and composition of sorted bacteria were characterized by 16S rRNA amplicon se-
quencing. (B) α-Diversity parameters (richness and Shannon effective count) for sorted antibody-positive (pos) and -negative (neg) bacteria. Two separate
experiments, #1 and #2, were performed. Groups were compared by one-way ANOVA and pairedWilcoxon test (*, P < 0.05; ns, not significant). (C) Correlation
analysis considering the Shannon effective count as displayed in B and bacteria binding in percent. Symbols represent the mean of two independent ex-
periments. (D) β-Diversity displayed as PCoA of generalized Unifrac distances. The plots depict comparison between antibody-positive samples from HDs and
CD patients (left plot) and between antibody-positive and -negative samples from HDs (middle) and CD patients (right). FSC, forward scatter; SSC, side scatter.
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Figure 4. High-microbiota-reactive intestinal IgA is cross-species reactive. Single OTUs are organized as a dendrogram (phylum to family, annotations
displayed in colors) based on the RDP taxonomic classification (Wang et al., 2007). Only OTUs occurring at a relative abundance of ≥0.5% in any positive
Kabbert et al. Journal of Experimental Medicine 6 of 14
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(OTU 7, 15, 18, 19, 20, 31, and 32). These taxa have previously been
reported to be coated by endogenous IgA (Fadlallah et al., 2018;
Magri et al., 2017; Palm et al., 2014; Sterlin et al., 2020). In con-
trast, some OTUs showed particularly strong enrichment by
single antibodies. This pattern was observed for antibodies de-
rived fromHDs aswell as CD patients (Fig. 4 and Fig. S2). Notably,
OTUs with an overall low relative abundance were targeted by
specific mAbs, e.g., Moraxella osloensis (OTU 45; HD2a7), Bacte-
roides acidifaciens (OTU 5757; HD3a103), Muribaculum sp. (OTU 4;
CD1a293), and Lactobacillus gasseri (OTU 39; CD2a146). Therefore,
IgA responses are not only directed against dominant members of
the microbiota but also target underrepresented populations of
the overall gut microbial communities. Our data demonstrate that
individual intestinal antibodies can bind a broad range of mi-
crobial species while exhibiting unique binding profiles. Impor-
tantly, we observed phylogenetically unrelated taxa among
selectively and commonly targeted OTUs, suggesting that single
monoclonal human IgA antibodies can bind to unrelated groups
of gut bacteria. We therefore conclude that cross-species reac-
tivity is one characterizing property of human intestinal IgA in
healthy and inflamed gut.
The mAbs tested here were expressed as human IgG1 anti-
bodies independently of their original isotype and subclass.
Therefore, it seems unlikely that the binding patterns described
herein rely on Fc-mediated interactions and glycan mod-
ifications. Nonetheless, glycan-mediated interactions between
mAbs and individual members of the gut microbiota have been
reported (Nakajima et al., 2018), and different mAbs may differ
in their precise glycan modification. To directly determine the
contribution of antibody glycan structures to microbiota bind-
ing, we deglycosylated a set of purified mAbs. Deglycosylation
did not affect the overall binding capacity of mAbs (Fig. S3, A
and B), suggesting that glycanmodifications do not contribute to
the observed microbiota-binding patterns.
Somatic mutations but not polyreactivity confer cross-species
binding and high microbiota reactivity
To examine whether polyreactivity was an important determi-
nant of cross-species reactivity of human intestinal mAbs, we
screened the HD and CD collections of IgA- and IgG-derived
antibodies for binding to a panel of seven unrelated antigens
commonly used to test for polyreactivity. Antibodies that showed
binding to more than two antigens were classified as polyreactive.
Based on this criterion, 23% of IgA antibodies fromHDs and 13%
from CD patients were polyreactive (Fig. 5 A and Fig. S3 C;
Benckert et al., 2011). Among IgG-derived antibodies, we found
similar frequencies of polyreactive antibodies (23% for HD
mAbs and 18% for CD; Fig. S3 D). Notably, polyreactive IgA and
IgG antibodies were observed at similar frequencies among
antibodies with no/low, intermediate, and high microbiota
reactivity. In addition, polyreactive antibodies were not over-
represented among antibodies with high binding capacity for
microbiota (Fig. 5 B and Fig. S3 D). Hence, correlation analysis
did not reveal any positive relationship between polyreactivity
and percentage of antibody-bound bacteria (HD IgA, P = 0.97;
CD IgA, P = 0.41). Because we did not find an overrepresenta-
tion of polyreactive antibodies among high-microbiota-binding
antibodies, we further investigated the possibility that the high
capacity for microbiota binding of human intestinal IgA might
rely on accumulated somatic mutations.
IgA- and IgG-derived antibodies from both HDs and CD patients
showed the typical pattern of highlymutated intestinal antibodies in
both heavy and light chain V gene sequences (Barone et al., 2011;
Benckert et al., 2011; Berkowska et al., 2015; Lindner et al., 2015;
Fig. 6 A and Fig. S3 E). No major difference was detected when
comparing the number of mutations in the nonselected collection of
antibodies to the set of antibodies with high microbiota-binding
fraction are displayed. Antibody specificity to a given OTU is displayed as enrichment index (as defined in the graph and determined as mean of two or more
replicate experiments). 16 commonly targeted OTUs enriched twofold by ≥3 mAbs are indicated in colors, marked by asterisks, and listed below the figure.
Selectively targeted OTUs (OTUs enriched by only a single mAb among the high-microbiota-reactive antibodies) are listed in black and marked by asterisks. The
lineage and taxonomic identity (closest species with a valid name and corresponding 16S rRNA gene sequence identity) of these denoted OTUs were obtained
using EZbiocloud (Yoon et al., 2017). Nonlisted phyla are as follows: Deinococcus-Thermus (green), Cyanobacteria (brown), and Deferribacteres (yellow).
Taxonomic classifications of OTUs are listed in Table S2.
Figure 5. High microbiota reactivity does not correlate with poly-
reactivity. (A) IgA mAbs were tested in at least two replicate experiments for
polyreactivity and classified as either polyreactive (black) or nonpolyreactive
(white). (B) Bar charts show the relative distribution of polyreactive and
nonpolyreactive HD-derived and CD patient–derived IgA antibodies among
antibodies with no/low, intermediate, and high microbiota reactivity. Corre-
lation between polyreactivity and microbiota reactivity was determined by
linear regression (HD IgA, P = 0.97; CD IgA, P = 0.41).
Kabbert et al. Journal of Experimental Medicine 7 of 14
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capacity (Fig. 6, A and B). The overall number ofmutations in heavy
or light chains of IgA-derived and IgG antibodies did not correlate
with their capacity to bind gut bacteria (Fig. 6 C), with the exception
of a positive correlation in HD-derived IgG light chains (Fig. S3 F).
To directly address the contribution of somatic mutations to
microbiota-binding capacity as well as specificity, we generated
the predicted GL variants of IgA antibodies with high microbiota-
binding capacity (Fig. S4, A and B). For all reverted HD-derived
antibodies and for the majority of antibodies (seven of nine) de-
rived from CD patients, the GL variant showed a significant loss of
microbiota binding compared with the mutated variant (Fig. 6 D
and Fig. S4 A). Our data therefore strongly suggest that in
the human gut, somatic mutations significantly contribute to
microbiota-binding capacity and cross-species reactivity of IgA.
Importantly, GL reversion of antibodies did not render antibodies
polyreactive. In fact, the polyreactive antibodies HD2a7, CD3a32
and CD3a565 lost polyreactivity after GL reversion (Fig. S4, C and
D), indicating that these antibodies might have become poly-
reactive during somatic hyper mutation and cross-species reac-
tive mAbs did not derive from originally polyreactive antibodies.
However, four CD-derived GL-variantmAbs retained sufficient
microbiota-binding capacity to allow for sort-based purification
of bound microbes. Two of these antibodies maintained or even
showed increased binding capacity to bacteria (CD2a148 and
CD3a549), and two mAbs showed reduced overall binding but
still recognized a sortable bacterial population (CD1a293 and
CD2a127) in their GL configuration (Fig. 6 D and Fig. S4 A).
Mutated and GL antibodies largely bound the same bacterial
species (Fig. 7 B), although often with differing efficiencies
(Fig. 7 C). β-Diversity analysis of populations bound by the
mutated antibodies and their corresponding GL variants
showed close clustering for CD2a148 and CD3a549 and similar
relative abundance of enriched OTUs (Fig. 7 A). There were
notable differences in the relative binding capacities of mutated
mAbs compared with their GL variants to multiple individual
OTUs (Fig. 7 C). Moreover, for two of the mAbs, CD1a293 and
CD2a127, the populations of bacteria bound by the mutated
version and GL variant were substantially different (Fig. 7 C).
For these two antibodies, some of the OTUs enriched by the
mutated antibodies were less abundant in the population of
bacteria bound by the GL variants, indicating that even though
GL reversion retained some microbiota-binding capacity, mu-
tations in these two antibodies contribute to their microbiota
specificity and/or binding strength.
Figure 6. Somatic mutations confer high
microbiota-binding capacity. (A and B) Num-
bers of somatic mutations in the heavy and light
chain V genes displayed for all IgA antibodies
obtained from HDs and CD patients (A) and
for high-microbiota-reactive IgA antibodies (B).
(C) Microbiota-binding capacity, displayed as
percentage of bound microbiota determined as
mean of two or more replicate experiments (for
antibodies showing microbiota binding ≥1%),
was correlated to the number of somatic muta-
tions in heavy and light chain V genes for indi-
vidual IgA antibodies. Mean microbiota-binding
capacity of selected high-microbiota-reactive mAbs
are shown in red. P values were obtained by
linear regression analysis. (D) Pairwise com-
parison of microbiota-binding capacity of mAbs
and their respective, predicted GL variant. Symbols
represent the mean value of two independent
experiments. Significance was tested by paired
Mann–Whitney U test, **, P < 0.01; ns, not
significant.
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Collectively, these data show that fecal microbiota binding was
unrelated to polyreactivity, whereas in most cases, GL reversion
impairedmicrobiota-binding capacity or altered antibody specificity
for themicrobiota. Therefore, our data demonstrate that a system of
affinity-matured IgA is one central feature of SIgA–microbiota in-
teractions in the healthy and inflamed gut of adult humans.
Discussion
Here we show that IgA and IgG antibodies derived from intes-
tinal plasmablasts/plasma cells in adult humans can bind to
a large proportion of fecal microbes. Such high microbiota-
binding capacity was observed for different microbiota config-
urations, including murine samples as well as human samples
obtained from either HDs or patients with IBD. Highmicrobiota-
binding capacity was associated with binding to a broad range
of phylogenetically diverse bacteria. We refer to this mode of
binding as cross-species reactivity (Pabst and Slack, 2020) and
speculate that Ig binding to bacteria may constitute an important
mechanism to regulate the gut microbiota and the integrity of
the intestinal mucosa. Cross-species reactivity does not make
any assumption about the mode of binding but points to inter-
esting functional consequences for intestinal antibody function
in the complex gut microbiota environment.
Figure 7. Somatic mutations contribute to the gut microbiota specificity of human IgA. Fecal bacteria bound by mAbs carrying somatic mutations and
their corresponding GL variants were obtained by cell sorting and analyzed by 16S rRNA gene amplicon sequencing in two independent sets of experiments, #1
and #2. (A) β-Diversity PCoA plots based on generalized Unifrac distances depict comparison between sorted positive samples of mutated antibodies (filled
symbols) and corresponding GL variants (open symbols). (B) Venn diagram depicts shared and selectively enriched OTUs in mAb-positive and GL-positive
samples. Selectively enriched OTUs are marked by asterisks, EZbiocloud identified, and listed (Yoon et al., 2017). (C) Dendrogram clustering of OTUs organized
(phylum annotations displayed in colors) based on the RDP taxonomic classification (Wang et al., 2007). Only OTUs occurring at a relative abundance ≥0.5% in
any positive fraction are displayed. Heat map shows log10-transformed relative abundances of OTUs.
Kabbert et al. Journal of Experimental Medicine 9 of 14
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In the setting of a highly complex and dynamically changing
ecosystem such as the gut microbiota, it is difficult to picture
how antibodies selectively binding to single bacteria can be
produced at functionally meaningful levels. How does the host
generate sufficient amounts of secretory antibodies to affect the
microbiota? A possible explanation is the concept of enchained
growth, which refers to antibody-mediated cross-linking and ag-
glutination of dividing bacteria (Moor et al., 2017). For instance,
Salmonella-specific antibodies primarily cross-link dividing bacte-
ria to enable agglutination of the pathogen in a situation in which
few targeted bacteria are diluted within a complex and numerous
endogenous microbiota (Moor et al., 2017). Cross-species–reactive
antibodies might add to this concept by contributing to the ag-
glutination of planktonic members of the microbiota.
Cross-species reactivity appears to be a feature of bothmouse
(Bunker et al., 2017) and human intestinal antibodies. However,
although cross-species reactivity was proposed to be mainly
achieved by “innate-like” polyreactive antibodies inmice (Bunker
et al., 2017), we demonstrate here that, in adult humans, IgA
cross-species reactivity typically depends on the accumula-
tion of somatic mutations. It is possible that these two mecha-
nisms of cross-species antibody reactivity may simply reflect a
fundamental difference between the two hosts. However, we
speculate that these seemingly contradictory findingsmay in fact
reveal distinct facets of the intestinal immune response, which
may act in concert to protect against pathogens and create
microbiota-reactive antibodies throughout life in both mice and
humans. At the outset, the newborn receives maternal anti-
bodies that help shape the microbiota (Pabst et al., 2016), and
provide protection while the immune system initially develops.
Subsequently, in young individuals with relatively few germinal
centers and little affinity maturation, polyreactive antibodies
may be the dominant mechanism of microbiota binding. Indeed,
such antibodies are prevalent in the gut of young mice (Bunker
et al., 2017) and are present at low frequency in our collection of
human antibodies. However, during aging, these may become
supplanted by affinity-matured antibodies that accumulate so-
matic mutations, thereby enabling or even enhancing cross-
species reactivity. Such antibodies are the distinguishing type
of highly microbiota-reactive antibodies described here and are
consistent with the well-documented finding of highly mutated
plasma cell repertoires in the human gut exposed to a complex
and dynamic environment and microbiota (Barone et al., 2011;
Benckert et al., 2011; Lindner et al., 2015).
Intriguingly, cross-species reactivity does not extend to all
members of the microbiota: some bacteria detected by se-
quencing did not show relevant binding by any of the tested
antibodies, whereas others were commonly targeted by differ-
ent mAbs or specifically enriched by single antibodies. Thus,
intestinal antibodies display unique and specific binding profiles
for distinct members of the gut microbiota. But what determines
which bacterial taxa are targeted?
Polyreactive antibodies, per definition, bind unrelated mol-
ecules. Thus, binding of polyreactive antibodies to different
bacterial species might function via unrelated antigens present
on the different bacteria. The enrichment of defined bacterial
taxa by intestinal antibodies as described in mice (Bunker et al.,
2017) and here in humans suggests at least some level of anti-
body specificity. In contrast, hypermutated antibodies abundant
in the human gut are likely to be the result of ongoing selection
for high-affinity binding. Cross-species reactivity of high-
affinity antibodies might rely on epitopes shared between dif-
ferent bacterial species such as conserved glycan structures or
highly conserved peptides (Rollenske et al., 2018; Bunker et al.,
2019; Diard et al., 2019 Preprint; Sterlin et al., 2020). The iden-
tification of epitopes targeted by IgA across multiple members of
the microbiota is the crucial next step to further understand the
phenomenon of cross-species reactivity and to dissect pathways
of how cross-species reactivity is achieved.
Notably, bacteria commonly targeted by antibodies isolated
from HDs were also bound by high-microbiota-reactive anti-
bodies from CD patients. Therefore, selective broad binding to
distinct OTUs seems to be a hallmark of intestinal IgA in both
healthy and inflamed intestine. Thus, in both situations, the
profile of IgA-targeted bacteria comprised commonly targeted
OTUs in addition to specific members of the microbiota. These
observations indicate that major changes in gut microbiota
composition as observed in IBD patients do not necessarily
dominate the microbiota specificity of IgA and are consistent
with our previous observation that alterations of the microbiota
do not rapidly result in major changes of the plasma cell rep-
ertoire (Lindner et al., 2015).
The presence of cross-species–reactive antibodies under
healthy and inflamed conditions might hint at the functional
importance of such antibodies. Cross-species reactivity may
contribute to efficient agglutination of opportunistic pathogens,
possibly including the endogenous microbiota as scaffolding. Yet
proinflammatory functions can also be envisioned, and cross-
species reactivity might further exacerbate the inflammatory
response to members of the microbiota. In particular, in sit-
uations of an impaired intestinal barrier such as in IBD patients,
cells in the lamina propria will encounter IgA-coated intestinal
bacteria. IgA coating of the bacteria has the potential to modu-
late the ensuing immune response. Depending on the precise
context, interaction with the IgA Fc receptor FcαRI can initiate
proinflammatory or inhibitory responses (Bakema and van
Egmond, 2011).
An important step in understanding the generation of
microbiota-targeting Ig responses and cross-species reactivity
might come from a deeper understanding of how somatic hy-
permutation shapes these antibodies. Indeed, our data suggest
that accumulating somatic mutations fundamentally contribute
to antibody cross-species reactivity. In adult humans, the con-
tinuous exposure to varied but structurally similar bacterial
antigens may favor the proliferation and differentiation of
B cells with cross-species specificity. In this context, an impor-
tant step forward may come from a deeper understanding of
which bacterial species contribute to the initial activation of the
B cell response and subsequent affinity maturation. Indeed,
when testing antibodies selected for high microbiota reactivity
to murine fecal samples, these antibodies also showed high
microbiota reactivity to human fecal material from HDs and
patients with IBD. This suggests that either closely related bac-
terial strains are present in all samples or that intestinal
Kabbert et al. Journal of Experimental Medicine 10 of 14









ation user on 26 N
ovem
ber 2020
antibodies are indeed directed against structurally similar bac-
terial antigens shared among different members of the micro-
biota, independent of the host.
Collectively, our data highlight a new facet of IgA: high
microbiota and cross-bacterial species reactivity of human in-
testinal IgA rely on somatic mutations. We propose that cross-
species-specific antibodies provide a mechanism to efficiently
interact with multiple microbial members and represent one of
the major mechanisms by which the intestinal immune system
interacts with the intestinal microbiome.
Materials and methods
Mice
Rag2-deficient mice and C57BL/6J WT mice were bred and
reared at RWTH Aachen University under specific pathogen–
free (SPF) conditions. Germ-free C57BL/6J mice were bred and
reared at the Laboratory for Animal Sciences at Hannover
Medical School. Animal workwas performed in compliance with
ethics regulations of German Law for the Protection of Animal
Welfare (Tierschutzgesetz) and approved by North Rhein-
Westphalia State Agency for Nature, Environment and Consumer
Protection (Landesamt fur Natur, Umwelt und Verbraucherschutz
Nordrhein-Westfalen).
Human fecal material
The human biomaterials were provided by the centralized bio-
material bank of theMedical Faculty of RWTHAachen University
(RWTH cBMB) and were used in accordance with the regulations
of the RWTH cBMB and the Ethics Vote 206/09 of the Ethics
Committee of the Medical Faculty of RWTH Aachen University.
Production of mAbs
Generation of mAbs from three HDs undergoing right-sided
hemicolectomy has been described before (Benckert et al.,
2011). None of the donors had a history of intestinal inflamma-
tion, and the samples showed no signs of inflammation as deter-
mined by macroscopic evaluation and histopathologic examination
of the adjacent mucosa (Benckert et al., 2011). A second collection
of antibodies was generated from surgical samples of three CD
patients undergoing ileocoecal resection (CD1, male, 25 yr old;
CD2, male, 47 yr; CD3, male, 22 yr) and were obtained after
signed informed consent in accordance with protocols reviewed
and approved by the Charité University Hospital institutional
review board (EA1/257/12).
Single B cell sorting
Intestinal plasmablasts/plasma cells were isolated as previously
described (Benckert et al., 2011). In brief, lamina mucosa and
propria were dissected from lamina muscularis mucosae by
blunt preparation, and 2–3-mm tissue pieces were digested us-
ing 0.1% DNase and 0.1% collagenase followed by discontinuous
Ficoll density gradient centrifugation (GE Healthcare). Purified
lamina propria lymphocytes were stained on ice with fluorochrome-
coupled anti-human CD38 FITC, anti-human CD27 PE, anti-human
CD19 PECy7, anti-human IgG APC (all from BD Bioscience) or anti-
human IgA APC (Jackson Laboratory). Single CD38+CD27+IgA+ or
CD38+CD27+IgG+ plasmablasts/plasma cells were sorted into 96-well
PCR plates using a FACSVantage cell sorter with Diva configuration
(BD Bioscience), snap frozen on dry ice, and stored at −80°C until
further processing.
PCR amplification and expression vector cloning
Single-cell cDNA synthesis and nested PCR amplification of IGG
or IGA and IGK or IGL genes was performed as described
(Benckert et al., 2011). All PCR products were sequenced before
and after cloning into previously described eukaryotic expres-
sion vectors (Tiller et al., 2008). In brief, PCR products of IgH
V(D)J and IGK Igk and IGL Igl VJ variable regions were cloned
into separate expression vectors encoding for the constant re-
gions of the human IgG1, IGK and IGL light chain to allow for
expression of all antibodies as fully human Fc-IgG1 antibodies. Ig
gene sequence analysis, including Ig gene usage, clonal rela-
tionships, IgG subclass, somatic mutations, IgH CDR3 length,
and positive charged amino acids, was performed using IgBlast
(http://www.ncbi.nlm.nih.gov/igblast/).
Expression and purification of recombinant antibodies
239T HEK cells were transiently transfected with equal amounts
of both corresponding IgH and IgL chain plasmids using a cal-
cium phosphate kit (Invitrogen; K2780-01). Transfected HEK
cells were cultured in Pro 293a Media (Lonza) supplemented
with 1 mM sodium pyruvate, 2 mM L-glutamine, and 100 U/ml
penicillin G–streptomycin (all from Gibco). Supernatants were
collected 60 and 72 h after transfection and filtered through a
sterile filter (0.20 µm) and stored at 4°C. Igs were purified from
supernatants using Protein A–based affinity chromatography
(Äkta Start; GE Healthcare Life Sciences). Protein A HiTrap
columns (GE Healthcare Life Sciences) were loaded with Ig-
containing supernatant and washed with 20 mM sodium-
phosphate buffer, and antibodies were eluted using 0.1 M
citric acid (pH 3.0), pH neutralized with 1 M Tris-HCl (pH 9.0).
Collected supernatants were concentrated and washed with
PBS, and antibodies were collected in PBS. Concentrations of
purified antibodies were determined by ELISA.
Deglycosylation of antibodies
To remove human IgG Fc N-glycan moieties by deglycosylation,
GLycINATOR (EndoS2) an endoglycosidase for hydroxylation of
β1,4 linkage of core GlcNAc residues, was used according to the
manufacturer’s instructions (GlycINATOR R; Genovis). Degly-
cosylation was performed with 1 unit of GlycINATOR/1 µg IgG
and incubated for 30 min at 37°C. Deglycosylation was con-
firmed by mass spectrometry and Western blot. Samples were
reduced with Tris(2-carboxyethyl)phosphine before electro-
spray ionization mass spectrometry analyses, desalted using a
C4 ZipTip (Millipore), and analyzed in MeOH:2-PrOH:0.2% FA
(30:20:50). The solutions were infused through a fused silica
capillary (internal diameter, 75 µm) at a flow rate of 1 µl/min
and sprayed through a PicoTip (internal diameter 30 µm; both
from New Objective). Nano-electrospray ionization mass spec-
trometry analyses of the samples was performed on a Synapt
G2_Si mass spectrometer, and the data were recorded with
MassLynx 4.2 software 2/2 (both from Waters). Mass spectra
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were acquired in the positive-ion mode by scanning an m/z
range from 100 to 5,000 daltons with a scan duration of 1 s and
an interscan delay of 0.1 s. The spray voltage was set to 3 kV,
source temperature 80°C, and cone voltage 50 V. The recorded
m/z data were then deconvoluted into mass spectra by applying
the maximum-entropy algorithm MaxEnt1 (MaxLynx) with a
resolution of the output mass 0.5 daltons/channel and Uniform
Gaussian Damage Model at the half height of 0.7 daltons.
Deglycosylation efficiency of human IgG1 was independently
analyzed by Western blot. Heat-denatured samples were sepa-
rated on a 12% acrylamide gel (Bio-Rad) and transferred onto a
nitrocellulose membrane (0.45 µm, Bio-Rad; 1620115). For de-
tection of IgG1 heavy chains, membranes were blocked with 5%
milk powder in PBS/0.1% Tween-20 overnight at 4°C and in-
cubated with HRP-conjugated anti-IgG1-HRP antibody (Jackson
ImmunoResearch; 109-035-098) for 1 h. To detect glycans,
membranes were blocked with Hepes 2% Tween-20 buffer,
washed twice with Hepes, and incubated with concanavalin-
A–HRP for 16 h at room temperature (0.2 µg/ml in Hepes,
0.05% Tween-20, and 1 mM CaCl2, MgCl2, MnCl2, and conca-
navalin A [Sigma-Aldrich; L6397]). HRP activity was detected
with ECL substrate (Bio-Rad).
ELISA
The concentration of recombinant antibodies was determined
by ELISA. ELISA 96 plates (NUNC Maxi Sorp) were coated with
1.25 ng/ml of anti-human IgG Fc (AffiniPure goat anti-human
IgG, Fcγ-specific; Jackson ImmunoResearch; 109-005-098) in
PBS. Plates were washed with PBS/0.05% Tween-20 and blocked
with PBS/2% BSA for 1 h at 37°C. Human serum IgG1 standard
(Sigma-Aldrich) and recombinant antibodies diluted in PBS/
0.05% Tween-20 at twofold dilution were incubated for 1.5 h at
37°C and detected with HRP-conjugated (Peroxidase AffiniPure
goat anti-human IgG, Fcy-specific; Jackson ImmunoResearch,
109–035-098) diluted in PBS/0.05% Tween-20 at a concentration
of 0.8 µg/ml (Jackson ImmunoResearch Laboratories) according
to the manufacturer’s instructions. ODs were measured at 450
nm, and antibody concentrations were determined using the
SpectraMax microplate reader and software (Molecular Devices)
and Excel 2010 (Microsoft).
Generation of GL variants
Sequences were analyzed by IgBLAST comparison with Gen-
Bank, and GL segments with the highest probability were de-
termined. The reverted sequences were generated as gBlock
double-stranded DNA fragments from IDT (Integrated Tech-
nologies) with included flanking primer and restriction sites. GL
(gBlock) fragments (100 ng/µl) and original vector plasmids
containing IgH and IgL sequences were digested with respective
restriction enzymes (all from NEB). Vector backbone was puri-
fied by gel electrophoresis in a 1.8% agarose gel, and gBlocks
were purified by PCR purification Kit (Qiagen). Ligation was
performed with T4 DNA ligase (NEB), and products were
transformed into competent 5-α E. coli cells (NEB). For each
antibody, several clones were analyzed, and the GL and original
insert sequences were confirmed with IgBLAST comparison
with GenBank and Gentle free software (GENtle). The molecular
weight of GL variants was validated byWestern blot analysis for
heavy and light chains according to standard procedures.
Bacterial flow cytometry and bacterial sort purification
by FACS
Fecal pellets from SPF Rag2-deficient and germ-free WT mice
were collected and human fecal material (from five HDs and five
ulcerative colitis patients) was obtained and stored at −80°C.
Murine fecal pellets or aliquots from human feces were ho-
mogenized in 1.5-ml tubes in 1 ml of filtered (0.2 µm) HBSS.
Homogenized samples were centrifuged at 500 rpm for 1 min,
and the process was repeated until the supernatant was clear of
debris. Clear supernatant was centrifuged at 8,000 rpm (VWR
Microstar 17R) for 8 min, and the supernatant was discarded.
The bacterial pellet was resuspended in 100 µl of filtered HBSS/
2% normal goat serum (Sigma-Aldrich) and passed through
a sterile cell strainer (40 µm). The OD600 was determined in a
1:100 dilution, and suspensions were adjusted to OD600 of 0.13 ±
0.01 or 0.2 ± 0.01 for human fecal suspensions (5 × 107/ml
bacteria). Antibody concentrations were adjusted to 1 µg/ml in
HBSS/2% normal goat serum. 2 µl of murine bacterial suspen-
sions were stained with 100 µl of diluted antibody, incubated on
ice for 20 min, and washed in 1 ml HBSS/2% goat serum at
13,000 rpm for 8 min at 4°C. The supernatant was discarded,
and pellets were resuspended in 100 µl anti-human IgG1 AF647
(1:200; 0.5 mg/ml, Alexa Fluor 647–conjugated AffiniPure Goat,
anti-human IgG [H + L], Jackson ImmunoResearch) and incu-
bated for 20 min on ice. 50 µl of Syto9 dye (Syto 9 green fluo-
rescent nucleic acid stain, 5 mM in DMSO; Thermo Fisher
Scientific) in HBSS was added and incubated for 10 min on ice.
For bacterial suspensions isolated from human fecal material,
2 µl of bacterial suspensions were stained with 5 µg/ml AF647-
directly conjugated mAbs for 20 min on ice followed by Syto9
staining and washing as described for murine samples. A mini-
mum of 100,000 Syto9-positive events were acquired for each
sample. For FACS purification, samples were prepared as de-
scribed above in replicates, pooled, and sorted on a FacsAria II
(BD). Sorted samples were centrifuged at 13,000 rpm for 8 min
at 4°C, and pellets were stored at −80°C.
16S rRNA gene amplicon sequencing and analysis
Bacterial DNA from human fecal samples was extracted via glass
bead preparation and further isolated using the QIAamp DNA
Stool Kit (Qiagen) according to the manufacturer’s protocol.
Metagenomic DNA of sort-purified murine bacterial samples of
mAb-positive and mAb-negative fractions and input material
was extracted using the Qiagen DNA isolation kit according to
the manufacturer’s instructions. OTU profiles obtained for fecal
material and isolated bacteria were highly comparable (not de-
picted). The V3/V4 regions of 16S rRNA genes were amplified
(35 cycles) using primers 515F and 816R. PCR amplicons were
purified by agarose gel electrophoresis (1.5%) followed by pu-
rification using a QIAquick Gel Extraction Kit (Qiagen). Empty
samples were included in the overall sample processing (FACS
buffer collected during cell sorting) and analyzed along with
H2O and buffer controls used during library preparation to
identify potential artifact sequences. DNA was quantified using
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the Quant-iT PicoGreen dsDNA Kit assay (Invitrogen), and PCR
products were stored at −20°C until sequencing. The amplicon
libraries were sequenced with single barcodes in paired-end
mode (2 × 300 nt) using MiSeq sequencer (Illumina Miseq;
Uniklinik/RWTH Aachen). Raw reads were processed using the
IMNGS platform based on the UPARSE approach (Edgar, 2013).
OTUs were clustered at a sequence identity of 97%, and only
OTUs occurring at a relative abundance >0.25% in at least one
sample were used for further analyses. Taxonomic assignment
was based on the Ribosomal Database Project (RDP) classifier
v2.11 (Wang et al., 2007) with a confidence cutoff of 80%, and
dendrogram clustering of OTUs (phylum to family) was based on
genomic sequence similarity obtained by the RDP taxonomic
classification (Wang et al., 2007). The lineage and taxonomic
identity (closest species with a valid name and corresponding
16S rRNA gene sequence identity) of relevant OTUs were ob-
tained using EZbiocloud (Yoon et al., 2017). Diversity and sample
composition analyses were performed using Rhea v2.0 in R
(Lagkouvardos et al., 2017). All 16S rRNA data are freely avail-
able under BioProject accession no. PRJNA622437.
Polyreactivity ELISA
Polyreactivity assays were performed as described previously
(Benckert et al., 2011). In brief, ELISA plates were coated with
50 µl of the respective antigens (10 µg/ml calf thymus DNA,
5 µg/ml human recombinant insulin, 10 µg/ml LPS, 5 µg/ml
flagellin, 10 µg/ml cardiolipin, 10 µg/ml human albumin, and
10 µg/ml KLH) in PBS, overnight at 4°C. ELISA plates were
washed three times with PBS and incubated with 50 µl of an-
tibody at 1, 0.25, 0.06, and 0.015 µg/ml in PBS for 1 h. Recom-
binant human mAbs mGO53 (nonpolyreactive; Wardemann
et al., 2003) and ED38 (high polyreactive; Meffre et al., 2004)
were used for comparison on each plate. ELISA plates were
developed with HRP-labeled goat anti-human IgG Fcy specific
antibody (Jackson ImmunoResearch; 109-035-098) at a con-
centration of 0.8 µg/ml with 2 mM EDTA and 0.05% Tween-20
and HRP chromogenic substrate (ABTS; Pierce). OD450 was
measured using a microplate reader (Molecular Devices) and
Soft-Max software (Molecular Devices). The cutoff value for
each plate was determined based on the highest OD450 value at a
concentration of 1 µg/ml of the nonpolyreactive control mAb
(mGO53). Antibodies showing binding to at least two different
antigens were considered polyreactive.
Statistical analysis
Statistical analysis for FACS-generated data was performed with
GraphPad Prism 7. P values ≤0.05 were considered significant.
Statistics for 16S rRNA gene amplicon analyses are described in
detail in Rhea (https://lagkouvardos.github.io/Rhea/; Lagkouvardos
et al., 2017).
Online supplemental material
Fig. S1 shows representative FACS plots of bacterial staining
with selected high-microbiota-reactive mAbs from HDs and CD
patients and mAb staining quantification of bacterial material
obtained from unrelated feces or aliquots of pooled fecal mate-
rial. Fig. S2 shows log10-transformed relative abundance of all
OTUs in HD and CD mAb-positive and -negative samples and
input material, with OTUs phylogenetically organized as a
dendrogram. Fig. S3 shows representative FACS plots of binding
capacity of mAbs or their deglycosylated counterparts and
quantification of independent experiments; summary of poly-
reactivity and microbiota reactivity for all tested IgA and IgG
mAbs derived from HDs and CD patients; overall distribution of
polyreactive IgG mAbs among the HD and CD antibody collec-
tions tested; relative distribution of polyreactive and non-
polyreactive IgG mAbs among no/low, intermediate, or high
microbiota-reactive mAbs; absolute number of mutations in
IgG H and L V genes; and correlation of number of mutations in
Ig genes to microbiota-binding capacity for HD- and CD-
derived IgG mAbs. Fig. S4 shows representative FACS plots of
microbiota-binding capacity of selected high-microbiota-reac-
tive HD- and CD-derived IgA mAbs before and after GL rever-
sion; representativeWestern blot analysis to validate themolecular
weight of heavy and light chains; polyreactivity ELISA repre-
sentations for selected high-microbiota-reactive HD- and CD-
derived IgA mAbs before and after GL reversion tested
against seven unrelated antigens; and a summary heat map
of polyreactivity and microbiota reactivity of selected high-
microbiota-reactive HD- and CD-derived IgA mAbs before
and after GL reversion. Table S1 contains Ig sequence analysis
of CD-derived IgA+ and IgG+ intestinal plasmablasts/plasma
cells and microbiota reactivity of tested mAbs. Table S2 lists
taxonomic classification of all identified OTUs in HD and CD
mAb–positive and –negative samples and input material.
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Figure S1. High-microbiota-reactive IgA antibodies bind a major fraction of the intestinal microbiota. (A) Representative FACS plots demonstrating
staining of bacteria (gated on forward/side scatter profile and Syto9-positive events) with selected high-microbiota-reactive HD and CD IgA-derived mAbs.
Numbers indicate mean percentage of gated events ± SD of at least four independent experiments. (B) Binding capacity of selected HD (open circles) and CD
(black circles) mAbs to microbiota over a large set of independent experiments. For HD mAbs only, binding to bacteria is displayed for unrelated fecal material
(white bars) or for aliquots of pooled identical fecal material (gray bars) of three independent experiments. Single dots represent independent experiments;
bars represent minimum to maximum values of microbiota reactivity for individual mAbs.
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Figure S2. Intestinal IgA binds to high- and low-abundance members of the microbiota. Single OTUs are organized as a dendrogram (phylum classi-
fication in colors). Dendrogram clustering of OTUs (phylum to family) was based on the RDP taxonomic classification (Wang et al., 2007). OTUs marked by
asterisks denote commonly or selectively targeted OTUs and are listed in Table S2. Taxonomic species annotation of asterisks marked OTUs was based on
EZbiocloud (Yoon et al., 2017). Only OTUs occurring at a relative abundance ≥0.5% in any positive or negative fraction are displayed. Heat map shows log10-
transformed relative abundances of OTUs.
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Figure S3. High microbiota reactivity does not rely on glycosylation or polyreactivity but is characterized by high numbers of somatic mutations.
(A) Representative flow cytometry staining of bacteria (gated on forward/side scatter profile and Syto9-positive events) with selected unmodified or de-
glycosylated high-microbiota-reactive antibodies. Numbers indicate percentage of gated events. (B) Comparison of microbiota-binding capacity of glycosylated
(white bars) and deglycosylated (gray bars) antibodies. Symbols denote independent experiments, bars showmeans, and lines connect data points obtained in
the respective experiments. Significance was tested by paired Mann–Whitney U test; ns, not significant. (C) IgA and IgG antibodies were ranked according to
their microbiota-binding capacity from non/low to intermediate and high reactivity (percentage binding depicted above plots). Antibodies were tested for
binding to a set of seven nonrelated antigens and classified as polyreactive (black) and nonpolyreactive (white). (D) Antibodies were tested for binding to a set
of nonrelated antigens and classified as polyreactive (black) and nonpolyreactive (white). Bar charts show the relative distribution of polyreactive and
nonpolyreactive HD and CD IgG antibodies among antibodies with no/low, intermediate, and high microbiota reactivity. Correlation between polyreactivity and
microbiota reactivity was determined by linear regression (HD IgG, P = 0.75; CD IgG, P = 0.02). (E) Numbers of somatic mutations in heavy and light chain V
genes displayed for all IgG antibodies obtained from HDs and CD patients. (F) Microbiota-binding capacity displayed as percentage of bound microbiota for a
given antibody was correlated to the number of somatic mutations in heavy and light chain V genes for all IgG antibodies from HDs and CD patients. P values
were obtained by linear regression analysis.
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Tables S1 and S2 are provided online as separate Excel files. Table S1 shows Ig gene sequence analysis of CD patient–derived IgA+
and IgG+ intestinal plasmablasts/plasma cells. Table S2 shows the taxonomic classification of detected OTUs based on 16S rRNA
gene amplicon sequence identity.
Figure S4. Somatic mutations confer high microbiota-binding capacity. (A) Representative FACS plots showing staining of bacteria (gated on forward/
side scatter profile and Syto9-positive events) with IgA mAbs carrying somatic mutations compared with staining of bacteria with antibodies in their predicted
GL configuration. Numbers indicate percentage of gated events. (B) Representative Western blot analysis to illustrate correct mass of heavy and light chains of
antibodies before and after GL reversion. (C) Polyreactivity ELISA (OD450) showing the binding of selected HD and CD IgA mAbs and their GL variants to the
standard set of seven unrelated antigens (insulin, cardiolipin, flagellin, KLH, LPS, albumin, and calf-thymus DNA). Antibodies were considered polyreactive
when binding to more than two unrelated antigens above cutoff (dashed red line: OD450 of mGO53 at 1 µg/ml minus background). (D) Heat map representation
of polyreactivity ELISA. Polyreactive mAbs or polyreactive GL variants are indicated by black squares. Data are representative of two independent experiments.
Kabbert et al. Journal of Experimental Medicine S4
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